News of interest

Check the latest COMET news

First real‑world validation of the SCENARIOS Raman‑SERS platform for total PFAS detection in human serum

Between 18 – 21 June 2025 the Laboratory of Applied Molecular Spectroscopy (LAMS) of FORTH/ICE‑HT (Patras, Greece) joined forces with colleagues at the University of Eastern Piedmont (UPO, Italy) and Alessandria Hospital (AOU-AL, Italy) (Figure 1), to give the new SCENARIOS Raman‑Surface‑Enhanced Raman Scattering (SERS) technology its first test on biological samples – a decisive step towards routine biomonitoring of per‑ and poly‑fluoroalkyl substances (PFAS) in exposed populations.

three researchers and a technical instrument at work
Figure 1. FORTH and UPO researchers around the LabRAM HR Evolution system, Alessandria, June 2025.From left: Dr Zoi Lada and Dr George Voyiatzis (LAMS-FORTH) with Dr Alessandro Croce (AOU-AL)

Working side‑by‑side in UPO’s Environmental and Molecular Toxicology Laboratory, the team:

  • Standardised the conditions for LabRAM HR Evolution Raman microscope (Horiba) for liquid analysis and verified wavelength and intensity calibration on site.
  • Optimised the ion‑pair extraction protocol that transfers all PFAS present – from long‑chain PFOA to emerging alternatives such as ADV_M3 – into a SERS‑friendly aqueous phase.
  • Demonstrated quantification down to 1 ppb in both spiked water and, crucially, human serum using replicated SERS measurements (Figures 1–2).
Figure 2. SERS fingerprint of  ADV_M3  at 1 ppb in human serum

“Seeing clear, reproducible Raman fingerprints of PFAS directly in serum was the breakthrough we were aiming for,”explain Dr. George Voyiatzis and Dr. Zoi Lada (FORTH/ICE‑HT). “It proves that SERS can complement – and eventually speed up – conventional LC‑MS workflows for population‑scale exposure assessment, ”commented at the end of the hard working days  Prof. Francesco Dondero (PI of the Italian team and Coordinator of the SCENARIOS project) (Figure 3).

The preliminary data were presented during the Interdisciplinary Symposium on One Health and PFAS held at the Hospital of Alessandria, sparking keen interest from clinicians eager for faster screening tools.

Why it matters

  • Total PFAS rather than single analytes – the ion‑pair approach enriches all anionic PFAS simultaneously, offering a holistic exposure metric.
  • Minutes instead of hours – Raman read‑out takes < 5 min per sample, compared with ≥ 120 min for targeted LC‑MS.
  • Portable‑ready – the same SERS substrates can operate with field‑deployable handheld Raman devices, paving the way for on‑site blood‑testing campaigns.

The SCENARIOS consortium will next validate the method on real serum from exposed Italian cohorts and benchmark it against reference LC‑HRMS data.

Figure 3.  FORTH/ICE-HT researchers and UPO SCENARIOS Coordinaror Prof. Francesco Dondero in front of the University of Eastern Piedmont “A. Avogadro”, Alessandria, celebrating the successful Raman-SERS validation of total PFAS detection in human serum (June 2025).